This is just a glimpse of the GLP-1 trends available to CivicScience clients. Want to see the full picture? Let’s talk.

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

Patients with overweight or obesity who used maridebart cafraglutide experienced significant weight loss at 1 year, according ...

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

By coincidence (they started before GLP -1 drugs were approved for slimming), a group of 56 doctors have just answered that ...

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...

Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

Pharmacy professor Nicole Albanese discusses the science behind drugs like Ozempic and Wegovy, their potential to treat other ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...